Celldex Therapeutics Inc
Abrir
SetorSaúde
31.41 -1.16
Visão Geral
Variação de preço das ações
24h
Mín
31.33
Máximo
32.16
Rendimento | 2.6M -79M |
|---|---|
Vendas | -60K 15K |
EPS | -1.18 |
Margem de lucro | -524,566.667 |
Funcionários | 198 |
EBITDA | -3M -84M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +59.09% upside |
Próximos Ganhos | 5 de ago. de 2026 |
|---|
Capitalização de Mercado | -330M 2.2B |
|---|---|
Abertura anterior | 32.57 |
Fecho anterior | 31.41 |
Sentimento de Notícias
By Acuity
50%
50%
162 / 342 Ranking em Healthcare
Celldex Therapeutics Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
